Home › Companies › ALDEYRA THERAPEUTICS INC. › 2023-2024

ALDEYRA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ALDEYRA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated October 13, 2026.

4Ballot items
127Asset managers
585Fund votes
June 4, 2024Meeting date

Results at a glance

Meeting of June 4, 2024: 4 items on ALDEYRA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 elected · 2 approved.

Material dissent

Elect Director: Nancy B. Miller-Rich 63% of votes cast Elected Director under 80%
Elect Director: Ben R. Bronstein, M.D. 66% of votes cast Elected Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALDEYRA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ALDEYRA THERAPEUTICS INC.

These tallies are ALDEYRA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALDEYRA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 4, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Nancy B. Miller-Rich	21,883,289	--	--	12,598,676	10,177,898	63%	Elected	—
Elect Director: Ben R. Bronstein, M.D.	22,697,358	--	--	11,784,607	10,177,898	66%	Elected	—
2. Ratification of Appointment of BDO USA, P.C	44,100,430	372,785	186,648	--	--	99.1%	Approved	—
3. Advisory Vote on Executive Compensation	31,493,319	2,862,040	126,606	--	10,177,898	92%	Approved	—

Source: ALDEYRA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the ALDEYRA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 127 asset managers that disclosed a ALDEYRA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Ben R. Bronstein, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%WITHHELD

FOR: 22,697,358WITHHELD: 11,784,607

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Election of two Class I Directors: Ben R. Bronstein, M.D.

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ben R. Bronstein, M.D.”): 22,697,358 for, 11,784,607 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class I directors until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 2,907,026 for, 5,225,872 withheld, 352,503 abstained.

FORWITHHOLD

FOR: 2,907,026ABSTAIN: 352,503WITHHOLD: 5,225,872

Largest asset managers voting on “Election of two Class I Directors: Ben R. Bronstein, M.D.” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	0	0	3,783,308	Withhold
BlackRock	1,740,689	0	0	For
Fidelity	961,375	0	0	For
Dimensional	0	0	546,755	Withhold
SEI	0	0	369,002	Withhold
CARILLON SERIES TRUST	0	283,577	0	Abstain
Equitable	85,187	0	56,690	Mixed
Charles Schwab	0	0	125,525	Withhold
TIAA	0	0	98,308	Withhold
QUANTITATIVE MASTER SERIES LLC	78,150	0	0	For
Lincoln Financial	0	0	48,794	Withhold
Managed Portfolio Series	0	27,962	0	Abstain
AIG/SunAmerica	0	0	22,952	Withhold
Jackson National	0	21,117	0	Abstain
Nationwide	5,467	0	14,655	Mixed
John Hancock	0	18,921	0	Abstain
Northern Trust	0	0	17,712	Withhold
American Century	0	0	17,136	Withhold
State Street	0	0	16,858	Withhold
Voya	0	0	16,086	Withhold
Brighthouse	0	0	15,823	Withhold
Pacific Life	14,881	0	0	For
Invesco	0	0	11,271	Withhold
Goldman Sachs	10,813	0	0	For
T. Rowe Price	0	0	10,567	Withhold

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

2. Elect Director: Nancy B. Miller-Rich

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%WITHHELD

FOR: 21,883,289WITHHELD: 12,598,676

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Election of two Class I Directors: Nancy B. Miller-Rich

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nancy B. Miller-Rich”): 21,883,289 for, 12,598,676 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class I directors until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 1,958,611 for, 6,174,287 withheld, 352,503 abstained.

FORWITHHOLD

FOR: 1,958,611ABSTAIN: 352,503WITHHOLD: 6,174,287

Largest asset managers voting on “Election of two Class I Directors: Nancy B. Miller-Rich” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	0	0	3,783,308	Withhold
BlackRock	1,740,689	0	0	For
Fidelity	0	0	961,375	Withhold
Dimensional	0	0	546,755	Withhold
SEI	0	0	369,002	Withhold
CARILLON SERIES TRUST	0	283,577	0	Abstain
Equitable	85,187	0	56,690	Mixed
Charles Schwab	0	0	125,525	Withhold
TIAA	0	0	98,308	Withhold
QUANTITATIVE MASTER SERIES LLC	78,150	0	0	For
Lincoln Financial	0	0	48,794	Withhold
Managed Portfolio Series	0	27,962	0	Abstain
AIG/SunAmerica	0	0	22,952	Withhold
Jackson National	0	21,117	0	Abstain
Nationwide	0	0	20,122	Withhold
John Hancock	0	18,921	0	Abstain
Northern Trust	17,712	0	0	For
American Century	0	0	17,136	Withhold
State Street	0	0	16,858	Withhold
Voya	0	0	16,086	Withhold
Brighthouse	0	0	15,823	Withhold
Pacific Life	14,881	0	0	For
Invesco	11,271	0	0	For
Goldman Sachs	0	0	10,813	Withhold
T. Rowe Price	0	0	10,567	Withhold

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

3. 3. Advisory Vote on Executive Compensation

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%

FOR: 31,493,319AGAINST: 2,862,040

Details: description as filed, official tally, votes by 127 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S NAMED EXECUTIVE OFFICERS.

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 31,493,319 for, 2,862,040 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S NAMED EXECUTIVE” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	3,783,308	0	For
BlackRock	1,740,689	0	For
Fidelity	961,375	0	For
Dimensional	0	546,755	Against
SEI	0	369,002	Against
CARILLON SERIES TRUST	283,577	0	For
Equitable	141,877	0	For
Charles Schwab	125,525	0	For
TIAA	98,308	0	For
QUANTITATIVE MASTER SERIES LLC	78,150	0	For
Lincoln Financial	38,300	10,494	Mixed
Managed Portfolio Series	0	27,962	Against
AIG/SunAmerica	22,952	0	For
Jackson National	0	21,117	Against
Nationwide	19,515	607	For
John Hancock	18,921	0	For
Northern Trust	17,712	0	For
American Century	17,136	0	For
State Street	16,858	0	For
Voya	16,086	0	For
Brighthouse	15,823	0	For
Pacific Life	14,881	0	For
Invesco	0	11,271	Against
Goldman Sachs	10,813	0	For
T. Rowe Price	10,567	0	For

Fund voting reports, all 40 managers: 7,493,420 for, 991,981 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 102 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S NAMED EXECUTIVE” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
PERCEPTIVE ADVISORS LLC	9,221,412	0	For
BlackRock	1,346,420	0	For
KENNEDY CAPITAL MANAGEMENT LLC	1,232,089	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,028,231	0	For
EAGLE ASSET MANAGEMENT INC	876,705	0	For
State Street	850,101	0	For
SEI	0	370,081	Against
Northern Trust	343,907	28	For
PNC BANK, NATIONAL ASSOCIATION	0	301,505	Against
MELLON INVESTMENTS Corp	0	225,990	Against
Palo Alto Investors LP	225,465	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	178,919	0	For
ACADIAN ASSET MANAGEMENT LLC	178,170	0	For
WOODSTOCK CORP	0	170,715	Against
Charles Schwab	125,525	0	For
Dimensional	0	101,664	Against
Nuveen	99,687	0	For
Vanguard	91,895	0	For
STRS OHIO	82,300	0	For
AllianceBernstein	56,690	0	For
CIBC Private Wealth Group LLC	51,458	0	For
T. Rowe Price	48,273	0	For
DE Shaw	47,521	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	44,708	0	For
FIRST MANHATTAN CO. LLC.	34,745	0	For

Institutional-manager reports, all 102 managers: 16,438,370 for, 1,411,839 against. Showing the 25 largest; see all in the interactive database.

4. 2. Ratification of Appointment of BDO USA, P.C

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.1% Approved · of votes cast

FOR 99.1%

FOR: 44,100,430AGAINST: 372,785

Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF BDO USA, P.C. AS ALDEYRA THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2024.

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of BDO USA, P.C”): 44,100,430 for, 372,785 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Appointment of BDO USA, P.C. The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 8,485,401 for.

FOR

FOR: 8,485,401

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF BDO USA, P.C. AS ALDEYRA THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOU” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	3,783,308	For
BlackRock	1,740,689	For
Fidelity	961,375	For
Dimensional	546,755	For
SEI	369,002	For
CARILLON SERIES TRUST	283,577	For
Equitable	141,877	For
Charles Schwab	125,525	For
TIAA	98,308	For
QUANTITATIVE MASTER SERIES LLC	78,150	For
Lincoln Financial	48,794	For
Managed Portfolio Series	27,962	For
AIG/SunAmerica	22,952	For
Jackson National	21,117	For
Nationwide	20,122	For
John Hancock	18,921	For
Northern Trust	17,712	For
American Century	17,136	For
State Street	16,858	For
Voya	16,086	For
Brighthouse	15,823	For
Pacific Life	14,881	For
Invesco	11,271	For
Goldman Sachs	10,813	For
T. Rowe Price	10,567	For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Largest ALDEYRA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 59,414,489 shares outstanding at the time of that meeting.

Fund voting reports: top ALDEYRA THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	6.37%
2	BlackRock	2.93%
3	Fidelity	1.62%
4	Dimensional	0.92%
5	SEI	0.62%
6	CARILLON SERIES TRUST	0.48%
7	Equitable	0.24%
8	Charles Schwab	0.21%
9	TIAA	0.17%
10	QUANTITATIVE MASTER SERIES LLC	0.13%

Institutional-manager reports: top ALDEYRA THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S…”, 2023-2024
#	Asset manager	% of shares outstanding
1	PERCEPTIVE ADVISORS LLC	15.52%
2	BlackRock	2.27%
3	KENNEDY CAPITAL MANAGEMENT LLC	2.07%
4	GEODE CAPITAL MANAGEMENT, LLC	1.73%
5	EAGLE ASSET MANAGEMENT INC	1.48%
6	State Street	1.43%
7	SEI	0.62%
8	Northern Trust	0.58%
9	PNC BANK, NATIONAL ASSOCIATION	0.51%
10	MELLON INVESTMENTS Corp	0.38%

Reported ALDEYRA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ALDEYRA THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Perceptive Advisors LLC	14.46%	DEF14A
BlackRock	6.40%	13F
Knoll Capital Management, LLC	6.05%	DEF14A
Vanguard Group	6.05%	13F
Todd C. Brady, M.D., Ph.D.	5.10%	DEF14A
Morgan Stanley	1.82%	13F
State Street	1.58%	13F
Dimensional Fund Advisors	1.48%	13F
Renaissance Technologies	1.22%	13F
Stephen G. Machatha, Ph.D.	1.21%	DEF14A

Percentages above are of 59,414,489 shares outstanding, as reported by ALDEYRA THERAPEUTICS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALDEYRA THERAPEUTICS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.

At ALDEYRA THERAPEUTICS INC.'s shareholder meeting held June 4, 2024, in the 2023-2024 proxy season, 127 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 585 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S… — ALDEYRA THERAPEUTICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALDEYRA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

ALDEYRA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.